Oncological outcomes after pancreatoduodenectomy for pancreatic ductal adenocarcinoma in octogenarians: case-control study.
Journal
BJS open
ISSN: 2474-9842
Titre abrégé: BJS Open
Pays: England
ID NLM: 101722685
Informations de publication
Date de publication:
10 07 2023
10 07 2023
Historique:
received:
01
12
2022
revised:
31
03
2023
accepted:
05
04
2023
medline:
13
7
2023
pubmed:
11
7
2023
entrez:
11
7
2023
Statut:
ppublish
Résumé
By the end of this decade, 70 per cent of all diagnosed pancreatic ductal adenocarcinomas will be in the elderly. Surgical resection is the only curative option. In the elderly perioperative mortality is higher, while controversy still exists as to whether aggressive treatment offers any survival benefit. This study aimed to assess the oncological benefit of pancreatoduodenectomy in octogenarians with pancreatic ductal adenocarcinoma. Retrospective multicentre case-control study of octogenarians and younger controls who underwent pancreatoduodenectomy for pancreatic ductal adenocarcinoma between 2008 and 2017. The primary endpoint was overall survival and the secondary endpoint was disease-free survival. Overall, 220 patients were included. Although the Charlson co-morbidity index was higher in octogenerians, Eastern Cooperative Oncology Group performance status, ASA and pathological parameters were comparable. Adjuvant therapy was more frequently delivered in the younger group (n = 80, 73 per cent versus n = 58, 53 per cent, P = 0.006). There was no significant difference between octogenarians and controls in overall survival (20 versus 29 months, P = 0.095) or disease-free survival (19 versus 22 months, P = 0.742). On multivariable analysis, age was not an independent predictor of either oncological outcome measured. Octogenarians with pancreatic ductal adenocarcinoma of the head and uncinate process may benefit from comparable oncological outcomes to younger patients with surgical treatment. Due to the age- and disease-related frailty and co-morbidities, careful preoperative assessment and patient selection is of paramount importance.
Sections du résumé
BACKGROUND
By the end of this decade, 70 per cent of all diagnosed pancreatic ductal adenocarcinomas will be in the elderly. Surgical resection is the only curative option. In the elderly perioperative mortality is higher, while controversy still exists as to whether aggressive treatment offers any survival benefit. This study aimed to assess the oncological benefit of pancreatoduodenectomy in octogenarians with pancreatic ductal adenocarcinoma.
METHOD
Retrospective multicentre case-control study of octogenarians and younger controls who underwent pancreatoduodenectomy for pancreatic ductal adenocarcinoma between 2008 and 2017. The primary endpoint was overall survival and the secondary endpoint was disease-free survival.
RESULTS
Overall, 220 patients were included. Although the Charlson co-morbidity index was higher in octogenerians, Eastern Cooperative Oncology Group performance status, ASA and pathological parameters were comparable. Adjuvant therapy was more frequently delivered in the younger group (n = 80, 73 per cent versus n = 58, 53 per cent, P = 0.006). There was no significant difference between octogenarians and controls in overall survival (20 versus 29 months, P = 0.095) or disease-free survival (19 versus 22 months, P = 0.742). On multivariable analysis, age was not an independent predictor of either oncological outcome measured.
CONCLUSION
Octogenarians with pancreatic ductal adenocarcinoma of the head and uncinate process may benefit from comparable oncological outcomes to younger patients with surgical treatment. Due to the age- and disease-related frailty and co-morbidities, careful preoperative assessment and patient selection is of paramount importance.
Identifiants
pubmed: 37432365
pii: 7222538
doi: 10.1093/bjsopen/zrad053
pmc: PMC10335165
pii:
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd.
Références
J Clin Oncol. 2009 Jun 10;27(17):2758-65
pubmed: 19403886
HPB (Oxford). 2009 Jun;11(4):282-9
pubmed: 19718354
J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1
pubmed: 17114007
Mol Clin Oncol. 2016 Mar;4(3):315-325
pubmed: 26998283
Br J Surg. 2020 Oct;107(11):1510-1519
pubmed: 32592514
Br J Surg. 2016 Jan;103(2):e7-9
pubmed: 26771471
J Clin Oncol. 2012 Jun 10;30(17):2036-8
pubmed: 22547597
Medicine (Baltimore). 2015 Sep;94(39):e1647
pubmed: 26426657
Br J Surg. 2021 Aug 19;108(8):976-982
pubmed: 34155509
Korean J Anesthesiol. 2017 Aug;70(4):390-397
pubmed: 28794833
JAMA. 2013 Oct 9;310(14):1473-81
pubmed: 24104372
Clin Gastroenterol Hepatol. 2021 May;19(5):876-884
pubmed: 32147593
Lancet. 2013 Mar 2;381(9868):752-62
pubmed: 23395245
Int J Surg. 2019 Dec;72:59-68
pubmed: 31580919
Ann Surg. 2023 Aug 1;278(2):260-266
pubmed: 35866656
J Am Geriatr Soc. 2010 Apr;58(4):783-7
pubmed: 20345862
Ann Oncol. 2012 Aug;23(8):2166-2172
pubmed: 22250183
Br J Surg. 2021 Jul 23;108(7):826-833
pubmed: 33738473
Ann Med Surg (Lond). 2021 Aug 15;69:102724
pubmed: 34457257
Ann Surg Oncol. 2021 Apr;28(4):2265-2272
pubmed: 33141373
Clin Epidemiol. 2018 Jul 09;10:789-797
pubmed: 30022856
J Geriatr Oncol. 2022 Nov;13(8):1208-1215
pubmed: 35931652
Br J Surg. 2021 Dec 17;109(1):89-95
pubmed: 34750618
Nat Rev Gastroenterol Hepatol. 2009 Dec;6(12):699-708
pubmed: 19806144
HPB (Oxford). 2020 Sep;22(9):1240-1249
pubmed: 32046922
J Geriatr Oncol. 2015 Mar;6(2):127-32
pubmed: 25555451
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
Anticancer Res. 2019 Feb;39(2):1005-1012
pubmed: 30711988
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Curr Probl Surg. 2019 Jul;56(7):260-329
pubmed: 31229137
Br J Surg. 2016 Jan;103(2):e10-1
pubmed: 26679284
J Geriatr Oncol. 2012 Jul 1;3(3):238-245
pubmed: 22712031
Br J Surg. 2016 Mar;103(4):463
pubmed: 26891214
Pancreas. 2013 Mar;42(2):249-53
pubmed: 22836862
Am J Surg. 2019 Sep;218(3):567-570
pubmed: 30728100
Am J Surg. 2020 Jul;220(1):135-139
pubmed: 31761298
Br J Surg. 2016 Jan;103(2):e83-92
pubmed: 26604018
Br J Anaesth. 2016 Feb;116(2):177-91
pubmed: 26787788
Ann Surg Oncol. 2016 Jun;23(6):2002-9
pubmed: 26795767
World J Gastrointest Oncol. 2017 Jan 15;9(1):30-36
pubmed: 28144397
Eur J Surg Oncol. 2013 Feb;39(2):171-8
pubmed: 22999411
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Pancreatology. 2017 Jan - Feb;17(1):146-149
pubmed: 28040425